Overview

The Gene Technology Act 2000, enacted by the Australian Parliament, established a regulatory system aimed at protecting the health and safety of people and the environment by managing the risks associated with gene technology. This legislation addresses the need for stringent oversight and regulation of activities involving genetically modified organisms to ensure public safety and environmental protection. The Gene Technology Regulator, as part of this Act, is responsible for assessing and approving licence applications related to gene technology dealings. The policy objective of the Act is to provide a framework for the safe and responsible use of gene technology, balancing innovation with public health and environmental safeguards. In the context of the proposed GM herpes simplex virus 1 for cancer therapy by Amgen Australia Pty Ltd, the Act ensures that thorough risk assessments are conducted and appropriate licence conditions are imposed to mitigate any potential risks to human health and the environment.

Scope and Application

The draft assessment outlined in the gazetted document pertains to an application from Amgen Australia Pty Ltd for the commercial supply of a genetically modified herpes simplex virus 1, intended as a treatment for skin cancer and other solid tumours not suitable for surgical removal. This application falls under the purview of Australia's gene technology regulatory system, which is responsible for managing risks to health and safety and the environment posed by gene technology. The Act applies specifically to entities seeking to engage in dealings with genetically modified organisms, in this case, Amgen Australia Pty Ltd, and the process is subject to both the Gene Technology Regulator and the Therapeutic Goods Administration (TGA) for comprehensive assessment of risks and therapeutic efficacy. The geographic scope of this regulation is national, overseen by the Commonwealth. Exclusions or exemptions from this legislation are not specified in the text, but the application process is thorough, incorporating a Risk Assessment and Risk Management Plan and inviting public submissions to ensure all potential risks are identified and managed. The licence conditions proposed are designed to facilitate ongoing oversight, ensuring compliance with health and safety standards.

Key Provisions

The key operative sections of the Gazette C2015G00585, which concern the proposed use of a genetically modified (GM) herpes simplex virus 1 for cancer therapy, include the assessment of licence application DIR 132 from Amgen Australia Pty Ltd (section 1). This application is for the use of a GM virus as a prescription-only treatment for skin cancer and other solid tumours not suitable for surgical removal. Additionally, section 2 details the preparation of a consultation Risk Assessment and Risk Management Plan (RARMP), which concludes that the proposed dealings pose negligible risk to human health and safety or the environment. Section 3 outlines the draft licence conditions proposed to ensure ongoing oversight of these activities. The obligations and requirements imposed by this legislation on the parties involved include the necessity for Amgen to not only apply for and receive a licence from the Gene Technology Regulator but also obtain approval from the Therapeutic Goods Administration (TGA) before the GM virus can be used as a therapeutic product. The TGA has regulatory responsibility for assessing the quality, safety, and efficacy of medicines, and they are concurrently considering an application from Amgen. The Office of the Gene Technology Regulator (OGTR) is responsible for managing the risk assessment and proposing draft licence conditions. It is also required to invite and consider written submissions from the public to inform the decision on whether to issue a licence. Under this legislation, any breaches of the requirements or conditions set forth could potentially lead to civil or criminal consequences. Although specific offences and penalties are not detailed within the Gazette, general provisions of the Gene Technology Act 2000 (Cth) would apply. This could include fines and imprisonment for violations related to non-compliance with licence conditions, which could be substantial depending on the severity of the breach. It is also possible that failure to comply with the TGA’s requirements could result in penalties under the Therapeutic Goods Act 1989 (Cth), including fines and imprisonment. The exact penalties would depend on the specific breach and the discretion of the court.